



Please type a plus sign (+) inside this box



PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
SUPPLEMENTAL FORM PTO-1449 (use as many sheets as necessary)				Application Number	10/016,969
				Filing Date	Dec 14, 2001
				First Named Inventor	Pittner, R.A.
				Art Unit	1646
				Examiner Name	Ruixiang Li
Sheet	1	of	3	Attorney Docket Number	0401-UTL-0

U.S. PATENT DOCUMENTS						
Examiner Initials *	Cite No. ¹	U.S. Patent Document		Publication Date MMDDYYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS							
Examiner Initials *	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ³
		Country Code ⁴	Number ⁴ -Kind Code ⁵ (if known)				

Examiner Signature	<i>Ruixiang Li</i>	Date Considered	7/16/2007
-----------------------	--------------------	--------------------	-----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number(optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

G:\LEGAL\PATENTS\0401\0401-UTL-ONDS 070804 1449.doc



Please type or print sign (+) in this box



PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO


SUPPLEMENTAL FORM PTO-1449 (use as many sheets as necessary)		Complete if Known	
		Application Number	10/016,969
		Filing Date	Dec 14, 2001
		First Named Inventor	Pittner, R.A.
		Art Unit	1646
		Examiner Name	Ruixiang Li
		Attorney Docket Number	0401-UTL-0
Sheet	2	of	3

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
RLi		Adrian TE, et al., "Lack of effect of pancreatic polypeptide in the rate of gastric emptying and gut hormone release during breakfast" Digestion. 1981 21:214-8.	
		Beltowski, J., et al., "What we know 10 years since its discovery?" Pol J Pharmaco. 2004;56:5-27.	
		Camilleri, M, et al., "Effects of vasoactive intestinal peptide and pancreatic polypeptide in rabbit intestine" Gut. 1981 22:14-8.	
		Cox, HM, et al., "The effecto neuropeptide Y and peptide YY on electrogenic ion transport in rat intestinal epithelia" J Physio. 1988 Apr;398:65-80.	
		Ebert, R., "Control of gastric emptying by regulatory peptides" Z Gastroenterol Verh. 1988 23:165-70.	
		Gustavsson S, et al., "Effects of vasoactive intestinal peptide and pancreatic polypeptide on small bowel propulsion in the rat" Gastroenterol. 1997 12:993-7.	
		Harding, RK, et al., "Identification and characterization of the emetic effects of peptide YY" Peptides 1989 10:24-4.	
		Kruger, DF, et al., "Clinical implication of amylin and amylin deficiency" Diabetes Educator 1999;25:389-398.	
		Martin, JR, "The Y1 receptor subtype mediates the cardiovascular changes evoked by NPY administered into the posterior hypothalamic nucleus of conscious rat" Brain Res. 2004 1002:11-20.	
		Nightingale, JM, et al., "Gastrointestinal hormones in short bowel syndrome. Peptide YY may be the 'colonic brake' in gastric emptying" Gut. 1996 Aug;39(2):267-72.	
		Okumura, T, et al., "Intracisternal injection of pancreatic polypeptide stimulates gastric emptying in rats" Neurosci Lett. 1994 178(1):167-70.	
		Pheng, et al., "Agonist- and antagonist-induced sequestration/internalization of neuropeptide Y Y ₁ receptors in HEK293 cells" British J of Pharma 2003 139:695-704	
		Pironi, L, et al., "Fat-reduced ileal brake in humans: a dose-dependent phenomenon correlated to the plasma levels of peptide YY" Gastroenterology. 1993 105:733-9.	
		Sainsbury, A, et al., "Y4 receptor knockout rescues fertility in ob/ob mice" Genes Dev. 2002 16:1077-88.	
RLi		Servin, AL, et al., "Peptide-YY and neuropeptide-Y inhibit vasoactive intestinal peptide-stimulated adenosine 3',5'-monophosphate production in rat small intestine: structural requirements of peptides for interacting with peptide-YY-preferring receptors"	
Examiner Signature	Ruixiang Li		Date Considered
			7/16/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this box ☐

PTO/SB/08A (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

SUPPLEMENTAL FORM PTO-1449 (use as many sheets as necessary)		Complete if Known			
		Application Number	10/016,969		
		Filing Date	Dec 14, 2001		
		First Named Inventor	Pittner, R.A.		
		Art Unit	1646		
		Examiner Name	Ruixiang Li		
Sheet	3	of	3	Attorney Docket Number	0401-UTL-0

RL:	Endocrinology. 1989 Feb;124(2):692-700.
	Taylor, IL, et al., "Effects of pancreatic polypeptide, caerulein, and bombesin on satiety in obese mice" Am J Physiol. 1985 248:G277-80.
	Taylor, IL, "Role of peptide YY in the endocrine control of digestion" J Dairy Sci. 1993 76:2094-101.
	Wager-Page, SA, et al., "Peripheral modulation of duodenal and colonic motility and arterial pressure by neuropeptide Y, neuropeptide Y fragment 13-36, peptide YY, and pancreatic polypeptide in rats: cholinergic mechanisms" Can J Physiol Pharmacol. 1993 71:768-75.
✓	Wimalawansa, "Amylin, Calcitonin Gene-related Peptide, Calcitonin, and Adrenomedullin: A Peptide Superfamily, Neurobiology, (2&3):167-239 (1997)
RLi	Young, AA, et al., "Dose-responses for the slowing of gastric emptying in a rodent model by glucagon-like peptide (7-36) NH ₂ , amylin, cholecystokinin, and other possible regulators of nutrient uptake" Metabolism. 1996 45:1-3.

Examiner Signature	Ruixiang Li	Date Considered	7/16/07
--------------------	-------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231.
NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.